To Assess the Safety of Continuous IV Administration of the CXCR4 Antagonist, Plerixafor (Mozobil), and Assess Its Impact on the Immune Microenvironment in Patients With Advanced Pancreatic, High Grade Serous Ovarian and Colorectal Adenocarcinomas.
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Plerixafor (Primary)
- Indications Colorectal cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions
- Acronyms CAM-PLEX
- 25 Jul 2017 Last checked against ClinicalTrials.gov record
- 20 Jul 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2017.
- 23 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.